Retour aux projets

15808.1 PFLS-LS

15808.1 PFLS-LS

Résumé

Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours

Textes supplémentaires

Abstract

The aim of this project is to complete key early developmental experiments for an anti-tumour peptide analogue therapy for patients with rare neuroendocrine tumours or acromegaly resistant, or poorly controlled, with available somatostatin analogues. The peptide analogue has high affinity for the two most important somatostatin receptors in growth hormone control, SSTR2 and 5. This novel tandem therapy will provide enhanced life expectancy, better clinical control and improved quality-of-life to the population of uncontrolled patients.

Participants

Alan Harris

Wirtschaftspartner

Alan.harris@sompharmaceuticals.com

Sompharmaceuticals S.A. Alan Harris 1066 Epalinges VD CH

Eric Grouzmann

Kontaktperson

eric.grouzmann@chuv.ch

CHUV Centre Hospitalier Universitaire Va Division de pharmacologie et toxicologie cliniques Eric Grouzmann Av. de Beaumont 29 1011 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2013-10-31
Date de fin
2015-07-31
Coûts totaux approuvés
CHF 270040.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%